SI-BONE Inc

SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 2008 and is headquartered in Santa Clara, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

SI-BONE reports record Q4 revenue, eyes global growth opportunities

SI-BONE's Q4 2022 performance reflects robust revenue growth and operational improvements, driven by increased surgeon engagement and product adoption.
The company's financial stability, strong cash position, and strategic focus on growth opportunities position it well for future success and market expansion.
While facing challenges such as undisclosed study enrollment and international growth pacing, SI-BONE's focus on operational efficiency and market opportunities presents a positive outlook for sustained growth and profitability.

SI-BONE Inc reports robust Q1 revenue growth and raises 2023 guidance

SI-BONE Inc had a strong Q1 performance with robust revenue growth and surgeon adoption. While facing some challenges with expense increases, the company is optimistic about future growth opportunities and aims for improved financial performance throughout 2023.

SI-BONE Inc reports robust Q2 growth and optimistic outlook

SI-BONE Inc's Q2 2023 showcased strong revenue growth, improved operational efficiency, and enhanced cash position.
Company's product portfolio, FDA clearances, and revenue guidance revisions underscore its growth potential and market competitiveness.
Challenges include managing increased operating expenses, evolving marketing strategies, and maintaining growth momentum.
Opportunities lie in expanding surgeon base, leveraging training programs, conducting market studies, and aiming for a strong second half performance.

SI-BONE reports record revenue in Q3 2023, eyes market expansion

SI-BONE's Q3 2023 earnings call showcased robust financial performance, strong market positioning, and growth prospects. With record revenue, increased guidance, and a focus on innovation and market expansion, SI-BONE is well-positioned for continued success in the medical device industry.

SI-BONE reports record revenue growth and strategic product launches

SI-BONE Inc delivered strong financial performance in Q4 2023, with record revenue, improved EBITDA, and a solid cash position for future growth initiatives.
The company's strategic strengths lie in its U.S. market dominance, innovative product launches, and positive revenue guidance for 2024.
Challenges include expanding international revenue, pricing competitiveness, and effective training for new products, while opportunities exist in market expansion and product innovation.
Overall, SI-BONE's performance highlights its resilience, growth potential, and strategic focus on driving innovation and market expansion in the medical device sector.

SI-BONE Inc reports robust Q1 revenue growth and strategic focus

SI-BONE Inc's Q1 performance reflects strong revenue growth and operational achievements, underpinned by strategic priorities and market differentiation. While facing challenges in expense management and profitability, the company is well-positioned to capitalize on opportunities through innovation and market disruption.

SI-BONE Inc reports strong Q2 earnings, eyes growth opportunities

SI-BONE Inc delivered robust financial performance in Q2 2024, driven by revenue growth, increased active physicians, and improved EBITDA.
The company's strengths lie in customer loyalty, innovation, leadership enhancements, and a clear path to financial sustainability.
Challenges include operational scalability, sustaining revenue growth, balancing innovation with cost control, and effective Board integration.
Opportunities for SI-BONE include accelerating revenue growth, expanding into new market segments, diversifying product offerings, and leveraging strategic Board additions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.

Humana is one of the 5 largest commercial payors in the U.S. and joins 36 other commercial health plans that offer coverage for the triangular iFuse Implant System only Humana is one of the 5 largest commercial payors in the U.S. and joins 36 other commercial health plans that offer coverage for the triangular iFuse Implant System only

SI-BONE, Inc. Announces that Humana Establishes Exclusive Coverage for iFuse in MIS SI Joint Fusion Procedures

SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q3 2020 Results - Earnings Call Transcript

SANTA CLARA, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2020.

SI-BONE, Inc. Reports Third Quarter 2020 Financial Results and 2020 Revenue Guidance

Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Si-Bone (SIBN) Report Negative Earnings Next Week? What You Should Know

SANTA CLARA, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2020 after market close on Monday, November 2, 2020. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report Third Quarter 2020 Financial Results on November 2, 2020

SANTA CLARA, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced preliminary unaudited revenue for the three and nine months ended September 30, 2020.

SI-BONE Reports Preliminary Unaudited Revenue for the Third Quarter 2020 and Provides Full Year 2020 Revenue Guidance

SANTA CLARA, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that Jeffrey Dunn, Chairman and CEO, will host a virtual surgeon panel from 10am to 11am ET on October 8, 2020. The panel will include four key opinion leaders focusing on the following topics:

SI-BONE, Inc. to Host Virtual KOL Surgeon Panel at NASS

SANTA CLARA, Calif., Sept.  02, 2020  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that the company will be participating in the upcoming 2020 Cantor Global Healthcare Conference. For the Cantor Global Healthcare Conference, SI-BONE’s management is scheduled for a Fireside Chat on Wednesday, September 16, 2020 at 3:20 p.m. Eastern Time / 12:20 p.m. Pacific Time. Interested parties may access a live and archived webcast of the events on the “Investors” section of the company’s website at:  www.si-bone.com .

SI-BONE to Present at the 2020 Cantor Global Healthcare Conference

SANTA CLARA, Calif., Sept.  01, 2020  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming Morgan Stanley 18th Annual Global Healthcare Conference and the 2020 Cantor Global Healthcare Conference.

SI-BONE to Present at the Morgan Stanley 18th Annual Global Healthcare Conference and the 2020 Cantor Global Healthcare Conference

SI-BONE is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: SI-BONE

35 U.S. payers now cover iFuse exclusively 35 U.S. payers now cover iFuse exclusively

SI-BONE, Inc. Announces Exclusive, Positive iFuse Coverage decision by Medica

SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q2 2020 Results - Earnings Call Transcript

SANTA CLARA, Calif., Aug.  03, 2020  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended June 30, 2020.

SI-BONE, Inc. Reports Second Quarter 2020 Financial Results

SANTA CLARA, Calif., July  30, 2020  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced today that the company will be participating in the upcoming 40th Annual Canaccord Genuity Growth Conference that is being held virtually.

SI-BONE to Present at the 40th Annual Canaccord Genuity Growth Conference

SANTA CLARA, Calif., July  21, 2020  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2020 after market close on Monday, August 3, 2020. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company’s website at:  www.si-bone.com . The webcast will be archived and available for replay for at least 90 days after the event.

SI-BONE To Report Second Quarter 2020 Financial Results on August 3, 2020

SANTA CLARA, Calif., June  01, 2020  (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced today that it has re-financed its existing credit facility. Proceeds from the new $40 million, five-year term loan will be used to repay SI-BONE’s prior $40 million term loan obligation in its entirety.  

SI-BONE, Inc. Announces $40 Million Debt Re-Financing

New positive coverage policy further validates acceptance of iFuse as an important treatment option for patients with chronic sacroiliac joint dysfunction

SI-BONE, Inc. Announces Aetna Establishes Positive Coverage for MIS SI Joint Fusion using the Triangular iFuse Implant System

SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q1 2020 Results - Earnings Call Transcript

Si-Bone (SIBN) delivered earnings and revenue surprises of -30.56% and -6.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Si-Bone (SIBN) Reports Q1 Loss, Misses Revenue Estimates

SANTA CLARA, Calif., May  04, 2020  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2020.

SI-BONE, Inc. Reports First Quarter 2020 Financial Results

SI-BONE, Inc. (SIBN) CEO Jeff Dunn on Q4 2019 Results - Earnings Call Transcript

New positive coverage policy is specific for FDA cleared implants placed across the SI joint and intended to promote bone fusion New positive coverage policy is specific for FDA cleared implants placed across the SI joint and intended to promote bone fusion

SI-BONE, Inc. Announces CIGNA Establishes Positive Coverage for MIS SI Joint Fusion using the iFuse Implant System

SANTA CLARA, Calif., Dec.  04, 2019  (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that Jeri Hilleman has joined its Board of Directors, effective immediately. Hilleman will also serve as chair of the audit committee.

SI-BONE Names Jeryl (“Jeri”) Hilleman to Board of Directors

SI-BONE, Inc.'s (SIBN) CEO Jeff Dunn on Q3 2019 Results - Earnings Call Transcript

Long-term follow-up results show excellent durability of clinical responses and positive radiographic outcomes for SI joint fusion using triangular titanium implants Long-term follow-up results show excellent durability of clinical responses and positive radiographic outcomes for SI joint fusion using triangular titanium implants

News for SI-BONE Inc Stock (SIBN)